Risks and benefits of azathioprine therapy
- Increased risk of lymphorna among inflammatory bowel disease patients treated with azathioprine and 6-mercapto- purine. Kandiel, A.; Fraser, A. G.; Korelitz, B. I.; Brensinger, C.; Lewis, J. D. // Gut;Aug2005, Vol. 54 Issue 8, p1121
Background: Inflammatory bowel disease (IBD) is commonly treated with immunomodulators such as azathioprine and 6-mercaptopurine (6-MP). Studies examining lymphoma risk in IBD patients treated with these medications have been underpowered and have yielded conflicting conclusions. Aims: The...
- Azathioprine and mercaptopurine: increased lymphoma risk. // Reactions Weekly;10/1/2005, Issue 1071, p5
Reports on the results of a meta-analysis which showed that the use of azathioprine or mercaptopurine appears to increase the risk of lymphoma in patients with inflammatory bowel disease compared with the general population. Number of observed and expected cases of lymphoma; Comment on the...
- Thiopurines increase lymphoma risk almost 3-fold. // Reactions Weekly;6/18/2011, Issue 1356, p4
The article relates that researchers from the U.S. and Europe have reported at the Digestive Disease Week 2011 that patients with inflammatory bowel disease (IBD) treated with thiopurines have an almost 3-fold increased risk of lymphoma.
- Altered FDG uptake patterns in pediatric lymphoblastic lymphoma patients receiving induction chemotherapy that includes very high dose corticosteroids. Sharp, Susan; Gelfand, Michael; Absalon, Michael // Pediatric Radiology;Mar2012, Vol. 42 Issue 3, p331
Background: Altered FDG uptake patterns were noted in certain lymphoblastic lymphoma patients during therapy. Objective: To describe these altered FDG uptake patterns and their relationship to chemotherapy. Materials and methods: Thirty-five FDG PET or PET/CT scans obtained in 11 children with...
- Rituximab. // Reactions Weekly;3/13/2004, Issue 992, p13
Discusses research being done on the side effects of rituximab in an elderly patient with non-Hodgkin's lymphoma. Reference to a study by Y. Tsutsumi and colleagues, published in the March 2003 issue of the "Leukemia and Lymphoma"; Development of hepatitis B virus reactivation with severe...
- Alpha-interferon for relapsed non-Hodgkin's lymphoma. Armitage, A. E.; Armitage, J. D.; Armitage, J. O. // Bone Marrow Transplantation;Nov2006, Vol. 38 Issue 10, p701
The article presents a case of patients with non-Hodgkin's lymphoma who had failed both standard therapy and autologous hematopoietic stem cell transplantation. They have received alpha-interferon as salvage therapy and rituximab. It was found that those patients with diffuse large B-cell...
- Adalimumab/infliximab. // Reactions Weekly;Apr2015, Vol. 1548 Issue 1, p17
The article presents a case study of an adult woman who developed arthritis while receiving treatment with infliximab for inflammatory bowel disease.
- The Current Management of Mantle Cell Lymphoma. Rule, Simon // Current Medical Literature: Leukemia & Lymphoma;2003, Vol. 11 Issue 2, p23
Focuses on the treatment of mantle cell lymphoma (MCL). Prognostic factors identified for MCL; Drugs for MCL; Survival rate of MCL patients who underwent Hyper-CVAD regimen.
- Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphomaâ€”a Nordic Lymphoma Group study. Jerkeman, M.; Anderson, H.; Dictor, M.; Kvaløy, S.; Åkerman, M.; Cavallin-Ståhl, E. // Annals of Hematology;Jul2004, Vol. 83 Issue 7, p414
The purpose of this study was to investigate the prognostic effects of four biological markers, BCL2, TP53, Ki-67, and P-glycoprotein, and their possible clinical relevance in addition to the international prognostic index (IPI) in diffuse large B-cell lymphoma (DLBCL). A total of 405 patients...